Intrinsic Therapeutics has raised $17.9 million in a new round of equity financing, according to an SEC filing posted today.
Intrinsic Therapeutics produces the Barricaid, an adjunct for lumbar limited discectomy to replace missing or damaged parts of the anulus to prevent re-herniation, disc collapse, the return of sciatica and potentially to help stave off low back pain.
Money in the round comes from 18 anonymous sources, according to the SEC filing, with the company looking to bring in another $2.3 million before closing out the round.
Intrinsic Therapeutics has not yet stated how it plans to spend funds raised in the round.